Enantio- and diastereocontrolled dopamine D1, D2, D3 and D4 receptor binding of N-(3-pyrrolidinylmethyl)benzamides synthesized from aspartic acid

Bioorganic and Medicinal Chemistry Letters

Volumn 9, Issue 6, 1999, Pages 841-846

  Thomas, Christoph ^a   Hübner, Harald ^a   Gmeiner, Peter ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYL GROUP; AMISULPRIDE; ASPARTIC ACID; BENZAMIDE DERIVATIVE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE RECEPTOR; EMONAPRIDE; METOCLOPRAMIDE; N (3 PYRROLIDINYLMETHYL)BENZAMIDE DERIVATIVE; SULPIRIDE; UNCLASSIFIED DRUG;

ARTICLE; DOPAMINERGIC SYSTEM; DRUG ACTIVITY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ENANTIOMER; REACTION ANALYSIS; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION;

ANIMALS; ASPARTIC ACID; BENZAMIDES; CATTLE; HUMANS; KINETICS; MODELS, CHEMICAL; PYRROLIDINES; RECEPTORS, DOPAMINE;

EID: 0344699370     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(99)00086-4     Document Type: Article

References (19)

1. For examples, see: Norman, M.H.; Kelley, J.L.; Hollingsworth, E.B. J. Med. Chem. 1993, 36, 3417, and references cited therein.
2. Harrington, R.A.; Hamilton, C.W.; Brogden, R.N.; Linkewich, J.A.; Romankiewicz, J.A.; Heel, R.C. Drugs 1983, 25, 451.
3. O'Connor, S.E.; Brown, R.A. Gen. Pharmacol. 1982, 13, 185. Schoemaker, H.; Claustre, Y.; Fage, D.; Rouquier, L.; Chergui, K.; Curet, O.; Oblin, A.; Gonon, F.; Carter, C.; Benavides, J.; Scatton, B. J. Pharmacol. Exp. Ther. 1997, 280, 83.
4. O'Connor, S.E.; Brown, R.A. Gen. Pharmacol. 1982, 13, 185. Schoemaker, H.; Claustre, Y.; Fage, D.; Rouquier, L.; Chergui, K.; Curet, O.; Oblin, A.; Gonon, F.; Carter, C.; Benavides, J.; Scatton, B. J. Pharmacol. Exp. Ther. 1997, 280, 83.
5. Iwanami, S.; Takashima, M.; Hirata, Y.; Hasegawa, O.; Usuda, S. J. Med. Chem. 1981, 24, 1224.
6. Racemic derivatives have been briefly mentioned in previous studies, see: Harada, H.; Morie, T.; Hirokawa, Y.; Yoshida, N.; Kato, S. Chem. Pharm. Bull. 1995, 43, 1364. Thominet, M.; Acher, J.; Monier, J.C. Ger. Offen. 2,901,170, 26 Jul 1979 (CA 1980, 92: 6406h).
7. Racemic derivatives have been briefly mentioned in previous studies, see: Harada, H.; Morie, T.; Hirokawa, Y.; Yoshida, N.; Kato, S. Chem. Pharm. Bull. 1995, 43, 1364. Thominet, M.; Acher, J.; Monier, J.C. Ger. Offen. 2,901,170, 26 Jul 1979 (CA 1980, 92: 6406h).
8. Gmeiner, P.; Orecher, F.; Thomas, C.; Weber, K. Tetrahedron Lett. 1995, 36, 381.
9. Thomas, C.; Orecher, F.; Gmeiner, P. Synthesis 1998, 1491.
10. Gmeiner, P.; Junge, D.; Kärtner, A. J. Org. Chem. 1994, 59, 6766.
11. Thomas, C.; Ohnmacht, U.; Niger, M.; Gmeiner, P. Bioorg. Med. Chem. Letters 1998, 8, 2885.
12. 2Ph), 62.4 (C-5), 126.8, 128.2, 128.7, 139.4 (arom.). NOE: Irradiation of H-3, H-2a gave a strong positive enhancement at H-4 and H-5b. Irradiation of H-4 gave a strong positive enhancement at H-3, H5-b, a weak positive enhancement at H-2b.
13. Hayes, G.; Biden, T.J.; Selbie, L.A.; Shine, J. Mol. Endocrinol. 1992, 6, 920.
14. Sokoloff, P.; Andrieux, M.; Besancon, R.; Pilon, C.; Martres, M.-P.; Giros, B.; Schwartz, J.-C. Eur. J. Pharmacol. 1992, 225, 331.
15. Asghari, V.; Sanyal, S.; Buchwaldt, S.; Paterson, A.; Jovanovic, V.; Van Tol, H.H.M. J. Neurochem. 1995, 65, 1157.
16. Ohnmacht, U.; Tränkle, C.; Mohr, K.; Gmeiner, P. Pharmazie 1999, in press, and references cited therein.
17. Ohmori, J.; Maeno, K.; Hidaka, K.; Nakato, K.; Matsumoto, M.; Tada, S.; Hattori, H.; Sakamoto, S.; Tsukamoto, S.; Usuda, S.; Mase, T. J. Med. Chem. 1996, 39, 2764.
18. For very recent SAR studies on D4 selective ligands, see: Löber, S.; Hübner, H.; Gmeiner, P. Bioorg. Med. Chem. Letters 1999, 9, 97.
19. short, D3 and D4.4 (10 μM). Incubation started by adding membranes with a protein concentration of 40-130 (μ/ml was run at 30 °C for 60 min and stopped by rapid filtration through GF/C filters coated in 0.3 % polyethylenimine, using an automated cell harvester (Inotech). Filters were washed 5 times with ice-cold 50 mM Tris-HCl pH 7.4 buffer containing 120 mM NaCl and counted in a MicroBeta TriLux (Wallac ADL).